General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Afinitor®

HR+/HER2-negative Advanced Breast Cancer

Afinitor is indicated for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.1

Advanced Neuroendocrine Tumors of Pancreatic Origin (pNET)

Afinitor is indicated for the treatment of unresectable or metastatic, well-or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

Advanced RCC

Afinitor is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy.


This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.


To contact us in your country of residence, please click here



Reference:

  1. Novartis Data on File